Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Up-regulation of thymidine phosphorylase

Cancer Journal

Volumn 13, Issue 4, 2007, Pages 247-256

  Saif, Muhammad Wasif ^a   Black, Glenda ^b   Roy, Shalija ^a   Bell, Diana ^b   Russo, Suzanne ^b   Eloubeidi, Mohamed A ^c   Steg, Adam ^b   Johnson, Martin R ^b   Zelterman, Daniel ^a   Diasio, Robert B ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

5 fluorouracil; Capecitabine (Xeloda); Dihydropyrimidine dehydrogenase; Pancreatic cancer; Radiotherapy; Thymidine phosphorylase

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; RECOMBINANT ERYTHROPOIETIN; THYMIDINE PHOSPHORYLASE; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPIRATION BIOPSY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; ENDOSCOPIC ECHOGRAPHY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOCYTE COUNT; LIVER METASTASIS; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; UPREGULATION; VOMITING; CHEMICALLY INDUCED DISORDER; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS TUMOR;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RNA, MESSENGER; SURVIVAL RATE; THROMBOCYTOPENIA; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 35748929435     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31813c12b8     Document Type: Article

References (34)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1998;48:6-29.
2. Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg. 1995;221:133-148.
3. Czito BG, Willett CG, Clark JW. Current perspectives on locally advanced pancreatic cancer. Oncology (Williston Park). 2000;14:1535-1545.
4. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer. 1981;48:1705-1710.
5. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998;16:317-323.
6. Crane CH, Janjan NA, Evans DB, et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol. 2001;29:9-18.
7. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
8. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291-297.
9. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology. 2000;61:199-203.
10. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme. Regul. 2001;41:151-157.
11. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
12. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 1998;58:685-690.
13. Tsukamoto Y, Kato Y, Ura M, et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm. Res. 2001;18:1190-1202.
14. Blanquicett C, Saif MW, Buchsbaum DJ, et al. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res. 2005;11(24 Pt 1):8773-8781.
15. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of CAP in human xenografts. Clin Cancer Res. 1999;5:2948-2953.
16. Saif MW, Eloubeidi MA, Russo S, et al. A phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of endoscopic genes related to outcome. J Clin Oncol. 2005;23:8679-8687.
17. Eloubeidi MA, Chen VK, Eltoum IA, et al. Endoscopic ultrasoundguided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. Am J Gastroenterol. 2003;98:2663-2668.
18. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Available at: http://www.fda.gov/cder/ cancer/ toxicityframe.htm. Accessed: February 9, 2007.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
20. Blanquicett C, Gillespie GY, Nabors LB, et al. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using cape-citabine and irradiation. Mol Cancer Ther. 2002;1:1139 -1145.
21. Johnson, MR, Wang K, Smith JB, et al. Quantitation of dihydropyrimi- dine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem. 2000;278:175-184.
22. Saif MW, Black G, Johnson M, et al. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Cancer Chemother Pharmacol. 2006;58:771-775.
23. Moghaddam A, Zhang HT, Fan TP, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA. 1995;92:998-1002.
24. Nishida M, Hino A, Mori K, et al. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull. 1996;19:1407-1411.
25. Mori K, Hasegawa M, Nishida M, et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol. 2000;17:33-38.
26. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322-1327.
27. Beck A, Etienne MC, Cheradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer. 1994;30A:1517-1522.
28. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 1998;58:685-690.
29. Nishimura G, Terada I, Kobayashi T, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep. 2002;9:479-482.
30. Terashima M, Fujiwara H, Takagane A, et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer. 2002;38:2375-2381.
31. Koizumi W, Saigenji K, Nakamaru N, et al. Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/ platelet-derived endothelial cell growth factor. Oncology. 1999;56:215-222.
32. Kakeji Y, Maehara Y, Shibahara K, et al. Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer. Oncol Rep. 1999;6:1213-1216.
33. Earle CC, Agboola O, Maroun J, et al. The treatment of locally advanced pancreatic cancer: a practice guideline. Can J Gastroenterol. 2003;17: 161-167.
34. Fisher BJ, Perera FE, Kocha W, et al. Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int JRadiat Oncol Biol Phys. 1999;45:291-295.